EuroEyes International Eye Clinic Limited Reports Strong Growth in Q1 2026 Eye Surgeries

Key Highlights

• Significant Increase in Surgeries: EuroEyes International Eye Clinic Limited (“EuroEyes” or the “Company”) reported a total of 7,598 eye surgeries performed group-wide for the first quarter of 2026 (1 January 2026 to 31 March 2026). This represents a notable 9% increase compared to 6,997 surgeries performed during the same period in 2025.
• Geographical Performance: The growth in eye surgeries was attributed primarily to the robust performance of the Company’s operations in Switzerland, suggesting strong demand and successful market penetration in this region.
• Preliminary and Unaudited Figures: The numbers provided are based on preliminary internal statistics and have not yet been audited. Final figures may differ from the current announcement.

Details of the Announcement

The Board of Directors of EuroEyes voluntarily released these preliminary results to keep shareholders and investors informed of the Company’s operational performance at an early stage. The 9% year-on-year growth in the number of surgeries signals a positive momentum in demand for the Group’s services and reflects successful execution of business strategies, particularly in Switzerland.

Management has emphasized that these statistics are based on internal estimates and are subject to changes upon final audit. Nevertheless, the continuing upward trend in the Group’s surgical volume may be interpreted as a sign of healthy business growth and potentially improved revenues for the first quarter of 2026.

Potential Impact for Shareholders

• Share Price Sensitivity: The announcement of a 9% increase in surgeries, especially driven by strong performance in Switzerland, is a positive operational indicator. If this translates into corresponding revenue growth and profitability, it could support the Company’s share price.
• Market Confidence: Early disclosure of strong operating data may boost investor confidence in the Company’s management and growth prospects.
• Caution on Preliminary Data: Investors should note that the figures are unaudited, and actual results may differ. The Company has advised investors to exercise caution when dealing in its shares until audited results are released.

Corporate Governance and Board Composition

The announcement was authorized by the Board, whose members include Dr. Jørn Slot Jørgensen (Chairman and Executive Director), Mr. Marcus Huascar Bracklo, Mr. Jannik Jonas Slot Jørgensen, and Professor Dan Zoltan Reinstein as executive directors, and Mr. Hans Helmuth Hennig, Ms. Katherine Rong Xin, and Mr. Philip Duncan Wright as independent non-executive directors. This diverse and experienced board structure is designed to provide effective oversight and strategic guidance.

Conclusion

The reported growth in surgeries for Q1 2026 is a key operational update that may influence investor sentiment and share price performance. Investors are encouraged to monitor subsequent disclosures, including audited results, for a fuller picture of the Company’s financial and operational health.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. The information discussed is based on preliminary, unaudited reports and may be subject to change. Investors should exercise caution and consult their financial advisers before making investment decisions.

View EUROEYES Historical chart here